Abstract:Objective To explore the serum level of Glucagon like peptide-1 in late-onset Alzheimer′s patients and its clinical significance.Methods Case control study.Collecting cerebral vascular disease fifty-five cases, diagnosed with late-onset Alzheimer′s disease sixty-one cases, type 2 diabetes mellitus fifty-one cases , type 2 diabetic patients combined with late-onset Alzheimer′s disease thirty-seven patients from the Shanghai East Hospital and partly Pudong area elderdly hospital during October 2013 to March 2014, and forty healthy persons as normal control from physical examination center of Shanghai East Hospital during September 2013 to February 2014.Measuring the concentrations of GLP-1,β-amyloid, Tau protein and other routinely used clinical tests in the serum of patients from the normal controls , cerebrovascular disease , late-onset Alzheimer′s disease, type 2 diabetes and type 2 diabetes mellitus combined with late-onset Alzheimer′s disease by ELISA method developed in our laboratory.The blood samples were also collected at three fixed time including fasting time ,1 hour after taking glucose , 2 hour after taking glucose, the concentrations of GLP-1 were determined in the LOAD group , T2DM group and the T2DM combined with LOAD group and normal control group.The concentrations of serum GLP-1 among groups were compared with single factor analysis of variance , and the concentrations of serum GLP-1 between the two groups were compared using LSD-t test.Analysing the correlation between GLP-1 and other indicators with Pearson analysis.Results The fasting GLP-1 levels of LOAD group were ( 123.4 ±20.8 ) nmol/L, and they were highest between the normal control group (78.6 ±6.0) nmol/L and the cerebral blood vessel disease group(89.0 ±8.7)nmol/L (F values were 3.46 and 1.98, P<0.05).The fasting GLP-1 levels of T2DM combined with LOAD group (157.9 ±28.6) nmol/L were higher than the LOAD group (123.4 ± 20.8) nmol/L (t =1.63,P <0.05), but there were no difference of the fasting GLP-1 levels between T2DM combined with LOAD group (157.9 ±28.6) nmol/L and T2DM group(153.8 ±18.0)nmol/L(t=0.96,P>0.05).Deficient secretion of GLP-1 after taking glucose 1 hour in most of the patients of T2DM combined with LOAD group (99.1 ±14.2) nmol/L, LOAD group(73.9 ±6.6 ) nmol/L and T2DM group (96.3 ±7.0 ) nmol/L could be concluded .The GLP-1 levels of T2DM combined with LOAD group after taking sugar 2 hour were (115.4 ±18.6)nmol/L ,and were higher than that of normal levels (63.3 ±6.2) nmol/L after taking sugar 2 hour(t=4.49,P<0.05).There were no difference between the GLP-1 levels of the LOAD group (73.6 ±5.8 )nmol/L and the GLP-1 levels of the normal group(63.3 ±6.2)nmol/L after taking sugar 2 hour (t=0.94,P>0.05).Pearson correlation analysis showed that the relationship of the levels of GLP-1 with Aβ( 1-42 ) and the levels of GLP-1 after taking glucose 1 h and 2 h were positively relative, and its coefficients of correlation were 0.401,0.436,0.722.Conclusions LOAD and T2MD are similar, and they have GLP-1 secretion shortage phenomenon after taking glucose , so monitoring dynamic change of GLP-1 after taking glucose may contribute to the auxiliary diagnosis of LOAD.

Clinical Significance of Detecting Glucagon Like Peptide-1 in Late-Onset Alzheimer′s Disease

The Association of Circulating Glucagon-Like Peptide-1 with Cognitive Functions and Biomarkers in Alzheimer's Disease

A Study on the Levels of Glucagon-like Peptide-1 and Glucose-dependent Insulinotropic Polypeptide in People with Different Glucose Tolerance Degrees

Impaired Secretion of Total Glucagon-Like Peptide-1 in People with Impaired Fasting Glucose Combined Impaired Glucose Tolerance

Dynamic Changes of Serum GLP-1 and Clinical Significance in Elderly Patients

Clinical Significance of Determination of Serum Cystatin C,lipoprotein (α) and High Sensitivity C-reactive Protein in Type 2 Diabetic Patients with Early Renal Impairment.

Level of Fasting Plasma Glucose, True Insulin, C-peptide and Amyloid Beta-protein in Patients with Alzheimer Disease

Relationship Between Early–phase Insulin Secretion and Blood Glucose Variability in Subject with Normal Glucose Regulation

Association Between Serum Γ-Glutamyl Transferase Concentration and Diabetic Peripheral Polyneuropathy in Type 2 Diabetics

Abnormal late postprandial glucagon response in type 1 diabetes is a function of differences in stimulated C-peptide concentrations

Evaluating the Effects of Glucagon-Like Peptide-1 Receptor Agonists on Cognitive Function in Alzheimer’s Disease: A Systematic Review and Meta-Analysis

Association Analysis of Acyl Ghrelin,des-Acyl Ghrelin and Its Ratio with Insulin Resistance in Patients with Type 2 Diabetes Mellitus

Study of CSF levels of glucose,true insulin,Aβ_(40) and Aβ_(42) in patients with Alzheimer's disease

Determination and significance of the concentration of urokinase-type plasminogen activator in serum in late-onset Alzheimer's disease

Potential roles of Glucagon-like peptide-1 and its analogues in cognitive impairment associated with type 2 diabetes mellitus

Study of relationship between serum alanine aminotransferase level and the different states of glucose metabolism

Association between 1,5-Anhydroglucitol and Acute C Peptide Response to Arginine among Patients with Type 2 Diabetes

Decreased Plasma Level of Lipoprotein Lipase Predicted Verbal Disfluency in Chinese Type 2 Diabetes Mellitus Patients with Early Cognitive Deficits

Impaired Glucose Tolerance is Associated with Enhanced Postprandial Pancreatic Polypeptide Secretion

Relationship between high sensitivity C-reactive protein and different glucose level in the elderly with abnormal glucose metabolism

A study on relationship between glucagon like peptide 2 and type 2 diabetes mellitus